SynthesisFrontiers in public health2026
Bayesian re-analysis suggests participation rather than referral underlies the benefits of social prescribing for chronic diseases.
Synthesis in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Social prescribing (SP) is increasingly implemented to address the social determinants of health in people with chronic diseases, yet uncertainty remains regarding its effectiveness and the mechanisms through which benefit is achieved. We performed a Bayesian re-analysis of randomized trials to distinguish overall treatment effects from implementation-related mechanisms. Methods: We systematically identified randomized controlled trials of SP following PRISMA 2020 guidelines. Bayesian hierarchical models were used to estimate intention-to-treat (ITT) effects on physical activity, evaluate dose-response relationships, quantify the additional benefit associated with program participation, examine patient-reported outcomes of link-worker SP, and summarize published economic evaluations. Results: 10 reports involving 4,840 participants were included. SP increased the likelihood of achieving recommended physical activity levels [OR 1.31, 95% credible interval (CrI) 1.07-1.67; posterior probability of benefit = 0.991]. No consistent dose-response relationship was identified (slope -1.29 benefit units, 95% CrI - 6.17 to 3.48). In contrast, high program participation was associated with an additional 0.26 clinically meaningful benefit units (95% CrI - 0.07 to 0.63; posterior probability of benefit = 0.940). Positive effects were observed across physical activity, body weight, blood pressure, mental health, health-related quality of life, patient activation, and functional activity. Exercise-oriented SP remained cost-effective under conventional willingness-to-pay thresholds, whereas the economic value of link-worker SP depended on implementation capacity. Conclusion: SP has a high probability of improving physical activity among adults with chronic diseases. Successful participation, rather than referral alone, appears to be the principal mechanism underlying these benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.